Phaseline

Targets › CAV1

CAV1 (Caveolin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Sep 2027.

May act as a scaffolding protein within caveolar membranes. Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. (UniProt, Q03135)

Open in Phaseline: the race on CAV1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rein TherapeuticsLTI-03
Caveolin-1-scaffolding-protein-derived peptide
CAV1Phase 2Idiopathic Pulmonary Fibrosis (IPF)Sep 2027

Conditions

Idiopathic Pulmonary Fibrosis (IPF) (1)

Modalities

small molecule (1)

Companies

Rein Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.